Enteral Formula Tolerance of Standard Tube Feedings
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Ontario
-
Ottawa, Ontario, Canada
- Bruyère Research Institute
-
-
-
-
Arkansas
-
Little Rock, Arkansas, United States
- University of Arkansas
-
-
Tennessee
-
Nashville, Tennessee, United States
- Vanderbilt University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- ≥18 years of age
- Currently tolerating enteral feeding
- Has enteral access
- Requires enteral tube feeding to provide 90% or more of their nutritional needs (without the use of modular(s)) for at least 21 days
- Having obtained his/her and/or his/her legal representative's informed consent.
Exclusion Criteria:
- Condition which contraindicates enteral feeding (i.e. intestinal obstruction)
- Lack of enteral access
- Any condition that would contraindicate use of the study product (i.e. need for severe fluid restriction, cow's milk protein allergy, other)
- Currently participating in another conflicting clinical study that would interfere with anticipated endpoints
- Judged to be at risk for poor compliance to the study protocol.
- Lack of informed consent.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
enterally fed adults
adult subjects with established enteral access receiving standard tube feeding formula
|
standard tube feeding formulas
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Daily percentage of caloric nutritional goal met
Time Frame: 21 days
|
21 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Daily percentage of protein goal met
Time Frame: 21 days
|
21 days
|
|
GI tolerance
Time Frame: 21 days
|
21 days
|
|
Adverse events and serious adverse events
Time Frame: 21 days
|
21 days
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 14.01.US.HCN
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.